May 7, 2020 / 12:26 PM / 21 days ago

BRIEF-Ovid Therapeutics Inc - Ov101 Met Study's Primary Objective Of Safety And Tolerability

Ovid Therapeutics Inc:

* OVID THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE 2 ROCKET TRIAL OF OV101 FOR THE TREATMENT OF FRAGILE X SYNDROME

* OVID THERAPEUTICS INC - OV101 MET STUDY’S PRIMARY OBJECTIVE OF SAFETY AND TOLERABILITY

* OVID THERAPEUTICS - OV101 PRODUCED STATISTICALLY SIGNIFICANT REDUCTIONS IN BEHAVIORAL, FUNCTIONAL SYMPTOMS IN INDIVIDUALS WITH FRAGILE X SYNDROME

* OVID THERAPEUTICS INC - PROVIDED PRELIMINARY FINDINGS FROM SKYROCKET, A NON-DRUG INTERVENTIONAL STUDY IN FRAGILE X SYNDROME.

* OVID THERAPEUTICS INC - SKYROCKET TRIAL DATA WILL HELP INFORM FUTURE STUDY DESIGN

* OVID THERAPEUTICS - TO REQUEST MEETINGS WITH REGULATORS TO DISCUSS DEVELOPMENT PATH, REGISTRATION PATHWAY FOR OV101 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below